<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02512471</url>
  </required_header>
  <id_info>
    <org_study_id>2014-64-2</org_study_id>
    <nct_id>NCT02512471</nct_id>
  </id_info>
  <brief_title>The Minimum Effective Volume of Ropivacaine in Ultrasound-guided Supraclavicular Block</brief_title>
  <official_title>The Minimum Effective Volume of Ropivacaine in Ultrasound-guided Supraclavicular Block</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huazhong University of Science and Technology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine the minimum effective volume of local anesthetic
      (ropivacaine 0.275% and 0.325%) required to produce an effective double-injection USG-SCB for
      surgical anesthesia in 90% of patients (MEV90) in young group (18-40 years) and in middle
      aged group (40-65 years) of patients scheduled for elective surgery of one upper limb distal
      to the shoulder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is based on biased coin design, and the volume of LA for the next patient is
      determined by the result of the last one. In the case of block failure, the volume will be
      increased by 2ml. Conversely, block success will result in either a reduction in volume by
      2ml (probability 11%) or no change in volume (probability 89%). A blinded assistant will
      assess sensory and motor blockade in each nerve territory ( the median, radial, ulnar and
      musculocutaneous nerves) at 10-min intervals up to 30 min after completion of the block.
      Finally, MEV90 is calculated by isotonic regression.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Minimum Effective Volume of Ropivacaine in Ultrasound-guided Supraclavicular Block</measure>
    <time_frame>up to 6 months</time_frame>
    <description>The Minimum Effective Volume (MEV) of Ropivacaine in Ultrasound-guided Supraclavicular Block is based on 55 measurements in 55 patients (secondary outcome measure: block success). MEV is determined by biased coin design method when all patients have been tested in the study.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Supraclavicular Brachial Plexus Block</condition>
  <arm_group>
    <arm_group_label>middle aged group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>brachial plexus block with ropivacaine 0.275%, MEV90 for USG-SCB</description>
  </arm_group>
  <arm_group>
    <arm_group_label>young group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>brachial plexus block with ropivacaine 0.325%, MEV90 for USG-SCB</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>brachial plexus block with ropivacaine 0.275%, MEV90 for USG-SCB (young group) brachial plexus block with ropivacaine 0.325%, MEV90 for USG-SCB (middle-aged group)</description>
    <arm_group_label>middle aged group</arm_group_label>
    <arm_group_label>young group</arm_group_label>
    <other_name>Naropin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. age between 18 and 65 years

          2. ASA 1-3

          3. body mass index between 18 and 35kg/m2

        Exclusion Criteria:

          1. inability to consent to the study

          2. pregnancy

          3. allergy to local anesthetics

          4. preexisting neuropathy or coagulopathy

          5. prior surgery in the supraclavicular region
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ailin Luo, MD.,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Anesthesiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Anesthesiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2015</study_first_submitted>
  <study_first_submitted_qc>July 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2015</study_first_posted>
  <last_update_submitted>February 18, 2016</last_update_submitted>
  <last_update_submitted_qc>February 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huazhong University of Science and Technology</investigator_affiliation>
    <investigator_full_name>Fang Gang</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>minimum effective volume</keyword>
  <keyword>ropivacaine</keyword>
  <keyword>ultrasound-guided supraclavicular block</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

